Brello Health Review: What Its GLP-1 Documentation Establishes—and What It Does Not

Brello Health’s public documentation answers a purchase question more clearly than an outcomes question: what would you be buying, and under which conditions? The company markets online access to clinicians and compounded semaglutide or tirzepatide, with bundled services and recurring prepaid plans. Those documents establish an advertised service, not evidence that Brello’s patients achieve the results reported in clinical trials. For an evidence-focused review, the distinction matters as much as the advertised monthly price.

This review examines public pages consulted October 19, 2026, separating commercial descriptions, contractual responsibilities and clinical research. Brello provides meaningful detail about checkout, pharmacy access and some refund deadlines. Yet its pages differ on delivery disputes, use different legal entity names and leave important treatment details unspecified. The practical task is not to treat every omission as a failure, but to identify which questions the documentation answers and which require confirmation before payment.

At a glance

Documented medicines: Brello identifies its GLP-1 offerings as compounded semaglutide and compounded tirzepatide; these preparations are not FDA approved.
Sources: [8] [4]
Semaglutide billing: Advertised from $133 per month as a three-month-plan average, with $399 collected initially and automatic renewal at $399 every 11 weeks until canceled.
Sources: [10]
Tirzepatide billing: The three-month plan starts at an advertised $166 monthly average and renews for $499 every 11 weeks; the six-month plan collects $894 initially and every 22 weeks.
Sources: [7] [6]
Separate responsibilities: Brello says clinicians provide consultations and identifies AP Max, Inc., doing business as Southend Pharmacy, for prescription fulfillment.
Sources: [12]
Narrow refund window: The detailed policy allows a refund less $50 after prescription issuance but before dispensing only when requested by email within 24 hours of the notification email.
Sources: [5]

Start with the medicine, not the ingredient’s reputation

Brello’s FAQ explicitly describes compounded semaglutide and compounded tirzepatide. Its semaglutide page includes medication, if approved, plus syringes with needles and injection instructions. That establishes an injection-related presentation, but the consulted documentation does not clearly identify the full formulation, concentrations, additives or anatomical administration route. Those are substantive product details, not interchangeable labels. Brello also states that compounded products are not FDA approved and that FDA does not evaluate their safety, effectiveness or quality.

FDA’s guidance supplies the appropriate boundary: compounded preparations do not undergo FDA premarket review, and FDA recommends them when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not demonstrate clinical inequivalence. Conversely, an ingredient name cannot establish that Brello’s preparation has the evidence supporting a particular approved product. Our guide to approved medicines and compounded preparations explains why these are separate questions.

The reviewed records do not establish Brello-specific clinical outcomes, comparative effectiveness or batch quality. They also do not establish that Brello uses semaglutide sodium or acetate; missing formulation detail is not evidence of salt use. Before purchasing, a useful documentary request is the exact prescribed preparation and its pharmacy label information, rather than a general assurance that it contains a familiar ingredient. That request clarifies what product is being offered without assuming either equivalence or inferiority.

Sources: [8] [10] [4] [1]

Who is responsible for the consultation and prescription?

Brello’s terms identify Brello, LLC as the entity owning or controlling the platform, while stating that virtual consultations are provided by clinicians using it. Brello says it is not itself a provider of clinical advice. The terms identify AP Max, Inc., doing business as Southend Pharmacy, as offering prescription fulfillment services. Separately, the tirzepatide page advertises shipment from a U.S.-based 503(a) pharmacy. These are documented company statements, not independent verification of pharmacy licensure or compliance.

One unusually consequential term says Brello does not confirm clinicians’ credentials or validate their standing with licensing boards, placing separate confirmation on the user. The consulted records do not identify the treating clinicians, their clinical entity or individual licenses. The SMS terms also name Brello, Inc., rather than Brello, LLC. That difference does not establish wrongdoing, but the documents do not explain the entities’ relationship or resolve which organization handles each responsibility.

For a prospective customer, the useful questions are specific: who will review the intake, which entity provides care, which pharmacy will dispense this prescription, and who handles an urgent medication concern? Identifying those parties is different from judging clinical quality, but it makes accountability clearer. Our discussion of what public provider documents can prove explains why a named partner, a licensing claim and independently confirmed credentials represent different levels of evidence.

Sources: [12] [7] [9]

Payment comes before the clinical intake

Brello’s enrollment page says no intake form is required before payment. After checkout, the customer completes an online form inside a telehealth account and should have government-issued identification ready. A clinician then reviews the information to determine whether the plan is appropriate. Shipment depends on approval, and the terms allow clinicians to deny care or prescriptions for safety concerns, possible misuse or other clinical or ethical reasons. Paying therefore does not guarantee a prescription.

The terms restrict service use to people located in the United States and require registrants to be at least 18. They also limit availability to certain U.S. locations. The consulted availability material exposes status categories but does not establish the exact state list. It would be inaccurate to describe the service as available nationwide. Nor do the records specify complete clinical admission criteria, required laboratory testing, contraindications or a Brello-specific BMI threshold.

The sequence makes advance clarification especially useful: confirm geographic availability and ask how any necessary testing or outside consultation is arranged before entering payment details. Brello’s homepage promises a full refund when someone is not approved, while the detailed policy ties that outcome to rejection without an issued prescription. Those distinctions matter because the financial rules change once clinical review and prescribing have occurred, even if medication has not yet arrived.

Sources: [12] [10] [4] [5]

The advertised monthly figure is not the payment schedule

Brello advertises semaglutide from $133 monthly and tirzepatide from $166 monthly, but these are averages for prepaid three-month plans, not documented monthly installment options. The semaglutide page specifies $399 today and every 11 weeks; tirzepatide specifies $499 every 11 weeks. The six-month tirzepatide page specifies $894 today, an advertised $149 monthly average and renewal every 22 weeks. Neither renewal interval equals the corresponding number of calendar months.

The table separates the headline plan from the actual collection schedule. Brello also markets Thrive Forward with semaglutide, sermorelin and NAD+ for $897 initially and every 11 weeks, displaying a former $997 price. Its tirzepatide version costs $997 on that schedule, displaying a former $1,099 price. Those bundle listings document commercial offerings; they do not, by themselves, establish added clinical benefit from combining the components.

Price qualifications deserve attention. The homepage says final pricing may vary by treatment plan and checkout, while medication pages advertise a new-member price lock with no extra fees, dose-related increases or renewal increases. The homepage describes a three-month minimum; a separate six-month offering also exists. Confirm which conditions govern the selected order. Brello’s terms additionally say the clinician does not participate in payer networks and neither the clinician nor Brello submits reimbursement claims for professional clinical services.

Selected advertised plans; medication remains subject to clinical approval.
Plan	Initial collection	Automatic renewal
Compounded semaglutide, three-month plan	$399; advertised from $133/month	$399 every 11 weeks
Compounded tirzepatide, three-month plan	$499; advertised from $166/month	$499 every 11 weeks
Tirzepatide, six-month plan	$894; advertised $149/month average	$894 every 22 weeks
Empowered+: semaglutide and NAD+	$598; three-month plan	$598 every 11 weeks
Empowered+: tirzepatide and NAD+	$698; three-month plan	$698 every 11 weeks

Sources: [10] [7] [6] [4] [13] [11] [12]

Trial evidence is not a Brello performance report

Clinical research can explain why these ingredient names attract attention without validating this provider’s preparations. STEP 1 randomized 1,961 adults with obesity, or overweight plus a weight-related condition, without diabetes, over 68 weeks. Both groups received lifestyle intervention. Mean weight change was −14.9% with studied subcutaneous semaglutide 2.4 mg weekly versus −2.4% with placebo. These details identify the research intervention, not instructions for a Brello patient.

In STEP 1, discontinuation because of gastrointestinal events occurred in 4.5% of semaglutide participants and 0.8% of placebo participants; Novo Nordisk funded the trial. The result does not establish outcomes for Brello, its compounded semaglutide, other routes or combination bundles. Our STEP 1 evidence guide examines the study’s scope. The central limitation is not that the trial lacks value, but that its intervention and setting must remain attached to its findings.

The same discipline applies to tirzepatide: evidence about a studied medicine should not become an implied Brello success rate. No Brello-specific outcomes study is established by the consulted documentation. Nor does the record support a claim that Empowered+ or Thrive Forward improves results over the GLP-1 component alone. Commercial bundle names, access to classes and prescription availability describe the service; they are not substitutes for measured, appropriately designed clinical evidence.

Sources: [3] [8] [13] [11]

Support is documented; the follow-up schedule is not

Brello lists Brello Rise, with hundreds of virtual fitness and nutrition classes, an app for tracking progress and connecting with the clinician, and a private Facebook community. It also advertises discreet packaging and shipping. Its tirzepatide page promises access to clinician and customer support throughout the process. These are identifiable service features, but the consulted pages do not define a clinical review frequency, renewal reassessment requirements or a guaranteed response time.

That distinction matters because clinical follow-up and subscription continuity serve different purposes. NIDDK describes medication selection as a discussion of benefits, side effects, health conditions, other medicines, family history and costs; follow-up concerns tolerance and response. For Brello, ask who reviews emerging concerns, how to reach that person securely and whether any laboratory work or outside visits cost extra. The documentation does not clearly establish coverage for those services or treatment of adverse effects.

There is also a pharmacy choice, but not a promise of identical bundled pricing elsewhere. Brello’s terms allow customers to notify the clinician or email info@brellohealth.com to use another pharmacy. The customer then pays that pharmacy directly and arranges collection or delivery; compounded prescriptions must transfer to another compounding pharmacy. Brello does not guarantee nonpartner pricing or services. Its terms also warn that email and SMS are unencrypted and should not carry sensitive health information.

Sources: [10] [7] [12] [2]

Delivery claims describe different milestones

Brello’s FAQ says approved orders in locations marked “Available (No Shipping Delays)” will ship within three to five business days, followed by a tracking email when available. That is a dispatch statement, not an arrival guarantee. The six-month plan page instead says the first shipment will arrive within three to five business days if approved, with the first three months of treatment; the second shipment is sent approximately 11 weeks later. These promises should not be collapsed into one uniform timeline.

The consulted documentation does not specify the carrier, temperature controls, complete storage conditions or expiration details. For injectable GLP-1 deliveries, FDA explicitly advises not using a product that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy. This is separate from Brello’s refund eligibility: its detailed policy asks customers to contact the pharmacy immediately about medication problems, regardless of elapsed time, but requires reporting within 48 hours of delivery to be considered for replacement or refund under that policy.

Delivery-dispute language also conflicts. The FAQ says carrier-confirmed delivery completes fulfillment and marked-delivered orders cannot be reshipped. The detailed policy treats confirmation as presumptive rather than conclusive evidence and allows an investigation after an email within 48 hours, a signed nonreceipt statement, address confirmation and a police report if theft is suspected. Our guide to reading delivery claims carefully helps distinguish transport promises from proof of acceptable receipt.

Sources: [8] [6] [5] [1]

Refund evidence depends on the stage of the order

The detailed refund policy offers a full refund for cancellation before clinical review, or rejection as an inappropriate candidate without an issued prescription. After prescribing but before dispensing, it allows the amount paid less a $50 professional service fee only if the customer emails within 24 hours after Brello sends notice that review is complete and a prescription has issued. The notification email’s timestamp controls. Once medication is dispensed, the policy describes it as nonrefundable.

Those exceptions are not reflected in the general terms’ broad statement that clinician and pharmacy fees are nonrefundable. Other boundaries are explicit: an incorrect customer-provided shipping address generally does not qualify for refund or reshipment unless Brello caused the processing error. During a nonreceipt investigation, a customer may have to purchase a replacement; if nonreceipt is confirmed, the policy promises a full replacement-order refund within ten business days after the investigation concludes, not guaranteed bank receipt within that period.

Brello repeatedly says customers can cancel anytime, but the consulted records do not establish the complete procedure or advance notice needed to stop renewal. Cancellation should not be read as a refund promise. Tirzepatide Transfer Protection is also conditional, not guaranteed dose continuation: it requires recent tirzepatide use within 30 days, prior prescription proof before review, completed intake and clinician review, and no previous refund under that protection. Its full procedural terms remain unconfirmed.

Sources: [5] [12] [7]

Questions & answers

Can I pay Brello’s advertised monthly amount each month?

The documented offers use monthly averages for prepaid packages, not a stated monthly installment option. Semaglutide collects $399 initially and every 11 weeks; three-month tirzepatide renews for $499 every 11 weeks. Six-month tirzepatide collects $894 initially and every 22 weeks. Confirm the selected checkout amount rather than budgeting from the headline average alone.

Sources: [10] [7] [6]

Does Brello guarantee approval after checkout?

No. Payment precedes the intake, and a clinician decides whether the plan is appropriate. Clinicians may decline care or prescribing for clinical, safety or ethical reasons. The detailed policy provides a full refund when the clinician finds someone unsuitable and no prescription has issued. That is different from a guarantee of medication access.

Sources: [10] [12] [5]

Is Brello available in my state?

The consulted records cannot establish the exact state coverage. Brello requires U.S. location and age 18 or older, but its terms restrict service to certain locations. The readable availability material does not identify every state. Ask whether both clinical service and shipment are currently available at your address before paying; U.S. eligibility is not nationwide availability.

Sources: [12] [8]

Whom should I contact about cancellation or a refund?

Brello publishes info@brellohealth.com and 1-888-BRELLO-1 for cancellation and refund inquiries. The post-prescription refund exception specifically requires an email within 24 hours of the notification, before dispensing; a telephone inquiry should not be assumed to satisfy it. Ask for written confirmation of any stopped renewal, since the complete renewal-cancellation procedure is not established in the consulted records.

Sources: [5]

What if a Brello package is marked delivered but is missing?

The detailed policy allows investigation if you email within 48 hours with a signed nonreceipt statement and correct-address confirmation, plus a police report when theft is suspected. However, the FAQ says marked-delivered medication cannot be reshipped. Ask Brello to reconcile those statements. A replacement may require payment while the investigation proceeds; reimbursement is conditional on confirmed nonreceipt.

Sources: [5] [8]

Does Transfer Protection guarantee my existing tirzepatide regimen?

No. The page says a first-order refund may be available if the clinician does not continue treatment at or near the current dose. Eligibility conditions include use within the prior 30 days and prescription proof before review. The clinician retains the prescribing decision, and the consulted documentation does not provide the protection’s complete terms or establish automatic eligibility.

Sources: [7] [12]

Our assessment

Brello documents a recognizable online service: clinician review after checkout, compounded GLP-1 offerings, a named prescription-fulfillment partner, prepaid renewals and several support features. That transparency is useful, especially where the pages state actual collection amounts and stage-specific refund deadlines. It does not establish provider-specific clinical effectiveness, verified credentials or equivalence between its preparations and products studied in trials. The strongest reasons for further clarification are concrete: incomplete formulation information, undefined follow-up timing, unresolved delivery and refund language, and an unspecified process for stopping renewal. Before payment, obtain the selected order’s billing terms, clinician and pharmacy identities, exact product details and applicable cancellation policy in writing. Brello’s public record supports evaluating an advertised service—not predicting an individual treatment result.

Visit Brello Health’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Brello Health Review: What Its GLP-1 Documentation Establishes—and What It Does Not

At a glance

01Start with the medicine, not the ingredient’s reputation

02Who is responsible for the consultation and prescription?

03Payment comes before the clinical intake

04The advertised monthly figure is not the payment schedule

05Trial evidence is not a Brello performance report

06Support is documented; the follow-up schedule is not

07Delivery claims describe different milestones

08Refund evidence depends on the stage of the order